Vaxcyte Inc is a biotechnology company focused on developing innovative vaccines to address significant infectious diseases
The company's research and development efforts center on utilizing its proprietary technology platform to design and produce a new generation of polysaccharide-based vaccines. By targeting a range of pathogens, Vaxcyte aims to enhance immune response and provide effective prevention measures against diseases that disproportionately affect public health. Through its work, the company seeks to contribute to a healthier global population by advancing the science of vaccinology.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's Prevnar 20. VAX-31 will advance to Phase 3 trials with plans for a pivotal study by mid-2025.
